ALF501 / Allife Medicine - LARVOL DELTA

First-in-human study of ALF501, polypeptide PSMA-targeted chimeric antigen receptor engineered natural killer cells) for castration-resistant prostate cancer (AACR 2023) - "ALF501 is safe and feasible for the treatment of CRPC, and has preliminary anti-tumor efficacy. This is a case study, and it is necessary to expand the patient sample size in the future to confirm whether there is a difference in efficacy for different patients."

P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Allife Medical Science and Technology Co., Ltd. | Unknown status ➔ Recruiting | Trial completion date: Dec 2021 ➔ Jun 2024 | Trial primary completion date: Dec 2020 ➔ Jun 2023

Enrollment open • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • NCAM1